Intervention

Enzalutamide

ClinicalTrials.gov intervention label

Clinical trials231
Recruiting41
Common conditions25
Lead sponsors shown15

Clinical trials

60 shown
A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]NCT07802704 · 2026-09-01
RECRUITING
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)NCT07723248 · 2026-08-03
RECRUITING
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate CancerNCT06616155 · 2026-06-01
RECRUITING
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate CancerNCT07570979 · 2026-05-25
RECRUITING
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)NCT07611110 · 2026-05-04
RECRUITING
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerNCT07287150 · 2026-03-11
RECRUITING
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPCNCT07226986 · 2025-12-05
RECRUITING
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid TumorsNCT07277270 · 2025-12-03
RECRUITING
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.NCT07028853 · 2025-09-28
RECRUITING
The COSMYC Trial (COmbined Suppression of MYC)NCT06922318 · 2025-08-19
RECRUITING
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology ClinicsNCT07406282 · 2025-07-22
RECRUITING
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)NCT06863272 · 2025-07-03
RECRUITING
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate CancerNCT05873192 · 2025-06-03
RECRUITING
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponseNCT06592924 · 2025-05-28
RECRUITING
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialNCT06632977 · 2025-02-06
RECRUITING
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate CancerNCT05726292 · 2025-01-06
RECRUITING
PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate CancerNCT06652607 · 2024-12-20
RECRUITING
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerNCT06236139 · 2024-11-26
RECRUITING
Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate CancerNCT06228053 · 2024-11-18
RECRUITING
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.NCT06629779 · 2024-10-22
RECRUITING
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL TrialNCT06499870 · 2024-09-06
RECRUITING
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)NCT06520345 · 2024-07-26
RECRUITING
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate CancerNCT06457919 · 2024-06-04
RECRUITING
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialNCT06378866 · 2024-06-03
RECRUITING
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering TherapyNCT06096870 · 2024-04-22
RECRUITING
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)NCT06136624 · 2023-12-31
RECRUITING
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)NCT06136650 · 2023-12-18
RECRUITING
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate CancerNCT05743621 · 2023-11-20
RECRUITING
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast CancerNCT06099769 · 2023-10-18
RECRUITING
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate CancerNCT06059118 · 2023-10-04
RECRUITING
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsNCT05914116 · 2023-08-17
RECRUITING
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerNCT05818683 · 2023-04-26
RECRUITING
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPCNCT05393791 · 2022-11-10
RECRUITING
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.NCT05422911 · 2022-08-31
RECRUITING
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate CancerNCT04986423 · 2021-09-08
RECRUITING
Sequential Testosterone and Enzalutamide Prevents Unfavorable ProgressionNCT04363164 · 2020-08-19
RECRUITING
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerNCT04221542 · 2020-03-04
RECRUITING
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate CancerNCT05406999 · 2020-02-01
RECRUITING
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasNCT04104776 · 2019-09-18
RECRUITING
Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate CancerNCT03753243 · 2018-12-03
RECRUITING
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaNCT03460977 · 2018-04-17
RECRUITING
Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate CancerNCT07852195 · 2027-01-06
NOT_YET_RECRUITING
Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT)NCT07782112 · 2026-11-01
NOT_YET_RECRUITING
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)NCT07711002 · 2026-10-01
NOT_YET_RECRUITING
A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor TherapyNCT07592910 · 2026-08-01
NOT_YET_RECRUITING
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574 · 2026-07-30
ENROLLING_BY_INVITATION
Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）NCT07104643 · 2025-08-01
NOT_YET_RECRUITING
A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)NCT07086651 · 2025-07-21
COMPLETED
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)NCT06991556 · 2025-07-07
ACTIVE_NOT_RECRUITING
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerNCT06764485 · 2025-03-13
ACTIVE_NOT_RECRUITING
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)NCT06691984 · 2024-12-09
ACTIVE_NOT_RECRUITING
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).NCT06551324 · 2024-10-21
ACTIVE_NOT_RECRUITING
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET StudyNCT06430411 · 2024-05-31
NOT_YET_RECRUITING
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate CancerNCT06312670 · 2024-05-16
COMPLETED
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate CancerNCT05730712 · 2024-03-08
COMPLETED
An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United StatesNCT06204302 · 2024-01-05
COMPLETED
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsNCT06120491 · 2023-11-21
ACTIVE_NOT_RECRUITING
An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World SettingsNCT06013475 · 2023-08-31
COMPLETED
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate CancerNCT05733351 · 2023-08-03
TERMINATED
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate CancerNCT05968599 · 2023-07-24
COMPLETED

Common conditions

Prostate Cancer73Metastatic Castration-Resistant Prostate Cancer23Castration-Resistant Prostate Carcinoma17Stage IVB Prostate Cancer AJCC v812Prostatic Neoplasms11Castration-resistant Prostate Cancer10Metastatic Prostate Cancer9Metastatic Prostate Carcinoma9Prostate Adenocarcinoma9Prostate Cancer Metastatic9Prostatic Neoplasms, Castration-Resistant9Recurrent Prostate Carcinoma9Cancer of the Prostate8Stage IV Prostate Cancer8Breast Cancer7Metastatic Hormone-Sensitive Prostate Cancer7Stage IV Prostate Cancer AJCC v87Metastatic Castration Resistant Prostate Cancer6Metastatic Prostate Adenocarcinoma6Stage IVA Prostate Cancer AJCC v86Metastatic Castration-resistant Prostate Cancer (mCRPC)5Adenocarcinoma of the Prostate4Castration Levels of Testosterone4Prostate Carcinoma Metastatic in the Bone4PSA Progression4

Trial status mix

COMPLETED104
RECRUITING41
ACTIVE_NOT_RECRUITING33
TERMINATED32
UNKNOWN7
NOT_YET_RECRUITING6
WITHDRAWN6
ENROLLING_BY_INVITATION2

Phase mix

PHASE2130
PHASE160
PHASE343
PHASE48
NA2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.